Qaasid News

Download Our App

Category: 3. Business

  • Town cashing-in on China’s billion-dollar appetite for luxury durian

    Town cashing-in on China’s billion-dollar appetite for luxury durian

    China’s insatiable appetite for durians has shaped up to be a nifty diplomatic tool.

    Beijing has signed a flurry of durian trade agreements, touting them as a celebration of bilateral ties — not just with major producers like Thailand, Vietnam and Malaysia, but also budding suppliers like Cambodia, Indonesia, Philippines and Laos.

    “In this durian competition, everyone’s a winner,” declared a state media article in 2024.

    The deals also dovetail with China’s investments in infrastructure in the region. The China-Laos Railway, launched in 2021, now transports more than 2,000 tonnes of fruit every day, most of them Thai durians.

    But this clamour to keep up with China’s appetite comes at a cost.

    Food safety concerns about Thai durians erupted last year, after Chinese authorities found in them a carcinogenic chemical dye believed to make the durians more yellow.

    In Vietnam, many coffee farmers pivoted to durians, driving up global coffee prices that were already affected by severe weather.

    And in Raub, a turf war has broken out. Authorities felled thousands of durian trees they said were planted illegally on state land. Farmers say they have been using the land for decades without any issue, and allege they are now being forced to pay a lease to continue farming there, or face eviction.

    Continue Reading

  • Nearly 40,000 cases of tater tots recalled, FDA says

    Nearly 40,000 cases of tater tots recalled, FDA says

    (Gray News) – Nearly 40,000 tater tots were recalled in multiple states.

    According to the Food and Drug Administration (FDA), McCain Foods USA Inc. has initiated a voluntary recall of two frozen potato products due to the potential presence of “clear hard plastic fragments.”

    A total of about 38,800 cases of tater tots were impacted for two specific frozen potato brands, Ore-Ida Tater Tots shaped potatoes and Sysco Imperial Potato Tater Barrel.

    Both products were distributed across multiple states, including the following:

    States impacted by the recall:

    • Alaska
    • Arizona
    • California
    • Colorado
    • Florida
    • Hawaii
    • Iowa
    • Idaho
    • Illinois
    • Kansas
    • Kentucky
    • Louisiana
    • Michigan
    • Minnesota
    • Missouri
    • Mississippi
    • Montana
    • Nebraska
    • New Mexico
    • North Dakota
    • Nevada
    • Oregon
    • Texas
    • Utah
    • Washington
    • Wisconsin

    The Ore-Ida Tater Tots, item number OIF00215A, are packaged in 30-pound clear, unlabeled poly bags and have batch codes including 1005479808 and 1005480444.

    The Sysco Imperial Potato Tater Barrel, item number 1000006067, is distributed by Sysco Corporation and packaged in 6/5-pound clear, unlabeled poly bags.

    Copyright 2026 Gray Local Media, Inc. All rights reserved.

    Continue Reading

  • A computational intelligence approach for classifying dental caries in X-ray images using integrated fuzzy C-means clustering with feature reduction and a weighted matrix scheme

  • Demarco, F. F. et al. Longevity of composite restorations is definitely not only about materials. Dent. Mater. 39 (1), 1–12. https://doi.org/10.1016/j.dental.2022.11.009 (2023).

    Google Scholar 

  • Askar, H. et al. Secondary caries: what is it, and how it can be controlled, detected, and managed? Clin. Oral Investig. 24 (5), 1869–1876. https://doi.org/10.1007/s00784-020-03268-7 (2020).

    Google Scholar 

  • Brouwer, F., Askar, H., Paris, S. & Schwendicke, F. Detecting secondary caries lesions: a systematic review and meta-analysis. J. Dent. Res. 95 (2), 143–151. https://doi.org/10.1177/0022034515611041 (2016).

    Google Scholar 

  • Signori, C. et al. Clinical relevance of studies on the visual and radiographic methods for detecting secondary caries lesions-a systematic review. J. Dent. 75, 22–33. https://doi.org/10.1016/j.jdent.2018.05.018 (2018).

    Google Scholar 

  • Gimenez, T. et al. What is the most accurate method for detecting caries lesions? A systematic review. Commun. Dent. Oral Epidemiol. 49 (3), 216–224. https://doi.org/10.1111/cdoe.12641 (2021).

    Google Scholar 

  • Moro, B. L. P. et al. Clinical accuracy of two different criteria for the detection of caries lesions around restorations in primary teeth. Caries Res. 56 (2), 98–108. https://doi.org/10.1159/000523951 (2022).

    Google Scholar 

  • Uehara, J. L. S. et al. Accuracy of two visual criteria for the assessment of caries around restorations: a delayed-type cross-sectional study. Caries Res. 57 (1), 12–20. https://doi.org/10.1159/000528730 (2023).

    Google Scholar 

  • Rahimi, H. M. et al. Deep learning for caries detection: a systematic review. J. Dent. 122, 104115. https://doi.org/10.1016/j.jdent.2022.104115 (2022).

    Google Scholar 

  • Duong, D. L., Kabir, M. H. & Kuo, R. F. Automated caries detection with smartphone color photography using machine learning. Health Inf. J. 27 (2), 14604582211007530, 1–17. https://doi.org/10.1177/14604582211007530 (2021).

    Google Scholar 

  • Yu, H. et al. A new technique for diagnosis of dental caries on the children’s first permanent molar. IEEE Access. 8, 185776–185785. https://doi.org/10.1109/ACCESS.2020.3029454 (2020).

    Google Scholar 

  • Geetha, V., Aprameya, K. S. & Hinduja, D. M. Dental caries diagnosis in digital radiographs using back-propagation neural network. Health Inform. Sci. Syst. 8 (1), 8, 1–14. https://doi.org/10.1007/s13755-019-0096-y (2020).

    Google Scholar 

  • Cantu, G. et al. Detecting caries lesions of different radiographic on bitewings using deep learning. J. Dent. 100 (103425), 103425. https://doi.org/10.1016/j.jdent.2020.103425 (2020).

    Google Scholar 

  • Vinayahalingam, S. et al. Classification of caries in third molars on panoramic radiographs using deep learning. Sci. Rep. 11 (1), 12609. https://doi.org/10.1038/s41598-021-92121-2 (2021).

    Google Scholar 

  • Lee, S. et al. Deep learning for early dental caries detection in bitewing radiographs. Sci. Rep. 11 (1), 16807. https://doi.org/10.1038/s41598-021-96368-7 (2021).

    Google Scholar 

  • Mao, Y. C. et al. Caries and restoration detection using bitewing film based on transfer learning with CNNs. Sens. (Basel). 21 (13), 4613. https://doi.org/10.3390/s21134613 (2021).

    Google Scholar 

  • Bayraktar, Y. & Ayan, E. Diagnosis of interproximal caries lesions with deep convolutional neural network in digital bitewing radiographs. Clin. Oral Invest. 26 (1), 623–632. https://doi.org/10.1007/s00784-021-04040-1 (2022).

    Google Scholar 

  • Kuhnisch, J., Meyer, O., Hesenius, M., Hickel, R. & Gruhn, V. Caries detection on intraoral images using artificial intelligence. J. Dent. Res. 101 (2), 158–165. https://doi.org/10.1177/00220345211032524 (2022).

    Google Scholar 

  • Vimalarani, G. & Ramachandraiah, U. Automatic diagnosis and detection of dental caries in bitewing radiographs using pervasive deep gradient based LeNet classifier model. Microprocess. Microsyst. 94 https://doi.org/10.1016/j.micpro.2022.104654 (2022).

  • Zhu, Y. et al. Faster-RCNN based intelligent detection and localization of dental caries. Displays 74, 102201. https://doi.org/10.1016/j.displa.2022.102201 (2022).

    Google Scholar 

  • Kumari, A. R., Rao, S. N. & Reddy, P. R. Design of hybrid dental caries segmentation and caries detection with meta-heuristic-based ResNeXt-RNN. Biomed. Signal Process. Control. 78, 103961. https://doi.org/10.1016/j.bspc.2022.103961 (2022).

    Google Scholar 

  • Imak, A. et al. Dental caries detection using score-based multi-input deep convolutional neural network. IEEE Access. 10, 18320–18329. https://doi.org/10.1109/ACCESS.2022.3150358 (2022).

    Google Scholar 

  • Park, E. Y., Cho, H., Kang, S., Jeong, S. & Kim, E. K. Caries detection with tooth surface segmentation on intraoral photographic images using deep learning. BMC Oral Health. 22 (1), 573, 1–9. https://doi.org/10.1186/s12903-022-02589-1 (2022).

    Google Scholar 

  • Kim, J., Lee, H. S., Song, I. S. & Jung, K. H. DeNTNet: Deep neural transfer network for the detection of periodontal bone loss using panoramic dental radiographs. Sci. Rep. 9 (1), 17615. https://doi.org/10.1038/s41598-019-53758-2 (2019).

    Google Scholar 

  • Hung, M. et al. Application of machine learning for diagnostic prediction of root caries. Gerodontology 36 (4), 395–404. https://doi.org/10.1111/ger.12432 (2019).

    Google Scholar 

  • Abdulaziz, A., Kheraif, A., Ashraf, Wahba, A. & Fouad, H. Detection of dental diseases from radiographic 2d dental image using a hybrid graph-cut technique and convolutional neural network. Measurement 146, 333–342. https://doi.org/10.1016/j.measurement.2019.06.014 (2019).

  • Roy, R., Ghosh, S. & Ghosh, A. Clinical ultrasound image standardization using histogram specification. Comput. Biol. Med. 120, 103746, 1–13. https://doi.org/10.1016/j.compbiomed.2020.103746 (2020).

    Google Scholar 

  • Wisaeng, K. Retinal blood-vessel extraction using weighted kernel fuzzy C-means clustering and dilation-based functions. Diagnostics 13 (3), 342, 1–21. https://doi.org/10.3390/diagnostics13030342 (2023).

    Google Scholar 

  • Xu, L., Liu, S. & Ma, J. Linear optimal filter for descriptor systems with time-correlated measurement noise. In 40th Chinese Control Conference (CCC), Shanghai, China, 3048–3053. https://doi.org/10.23919/CCC52363.2021.9549878 (2021).

  • Mardiris, V. & Chatzis, V. A configurable design for morphological erosion and dilation operations in image processing using quantum-dot cellular automata. J. Eng. Sci. Technol. Rev. 9 (2), 25–30. https://doi.org/10.25103/jestr.092.05 (2016).

    Google Scholar 

  • Yu, K., Jiang, L., Fan, J. S., Xie, R. & Lan A feature-weighted suppressed possibilistic fuzzy c-means clustering algorithm and its application on color image segmentation. Expert Syst. Appl. 241, 122270, 1–39. https://doi.org/10.1016/j.eswa.2023.122270 (2024).

    Google Scholar 

  • Yang, M. S. & Nataliani, Y. A. Feature-reduction fuzzy clustering algorithm based on feature-weighted entropy. IEEE Trans. Fuzzy Syst. 26 (2), 817–835. https://doi.org/10.1109/TFUZZ.2017.2692203 (2018).

    Google Scholar 

  • Xu, S. et al. Semi-supervised fuzzy clustering algorithm based on prior membership degree matrix with expert preference. Expert Syst. Appl. 238, 121812. https://doi.org/10.1016/j.eswa.2023.121812 (2024).

    Google Scholar 

  • Goh, T. Y., Basah, S. N., Yazid, H., Safar, M. J. A. & Saad, F. S. A. Performance analysis of image thresholding: Otsu technique. Measurement 114, 298–307. https://doi.org/10.1016/j.measurement.2017.09.052 (2018).

    Google Scholar 

  • Faragallah, O. S., Hoseny, H. M. E. & Sayed, H. S. E. Efficient brain tumor segmentation using OTSU and K-means clustering in homomorphic transform. Biomed. Signal Process. Control. 84, 104712, 1–14. https://doi.org/10.1016/j.bspc.2023.104712 (2023).

    Google Scholar 

  • Qayyum, A. et al. Dental caries detection using a semi-supervised learning approach. Sci. Rep. 13, 749, 1–11. https://doi.org/10.1038/s41598-023-27808-9 (2023).

    Google Scholar 

Continue Reading

  • Special advisory: daytime winter weather parking ban in effect on Sunday, January 11 from 10 am to 7 pm

    Due to weather conditions, a daytime winter weather parking ban will be in effect on Sunday, January 11 between 10 am and 7 pm across Ottawa. These hours might be extended if additional time is needed to complete winter road operations. Alternative parking during a parking ban can be found by visiting the Winter Parking webpage. Please be sure to remove your vehicle when the ban ends if you use it. 

    During a winter weather parking ban, parking is prohibited on city streets so crews can plow easily and effectively. Vehicles parked on the street during a ban may be ticketed and towed. On-street monthly parking permit holders are exempt from this restriction when they are parked in residential parking permit zones.

     

    Available parking

    During winter weather parking bans, residents will have access to select OC Transpo park and rides as well as certain recreation centres. Some City parking garages are available for parking during winter parking bans, however it is important that residents take note of what time they need to remove their car. Visit our winter parking web page for more information about which City facilities are available during winter weather parking bans.

     

    Commercial main streets

    To help residents shop local, some commercial main streets are exempt from winter parking bans. When a parking ban is called during winter weather events, residents can park in the identified areas while observing all posted signage and pay and display requirements.

     

    Be in the know about snow

    • Subscribe to our electronic email alerts. If you subscribe to e-Alerts, you will receive notification each time a winter weather parking ban is put in place, extended or lifted. There is no charge for this service, and you can unsubscribe at any time. 
    • Follow us on Facebook, Bluesky and X to receive updates.
    • Residents can also download the City of Ottawa app on their Android or Apple device to receive up-to-date information on winter parking bans and other City news.

     

    For more winter parking information, please visit the winter parking web page.

     


    Continue Reading

  • Alberta auto insurers lost more than $1B in 2024: report

    Alberta auto insurers lost more than $1B in 2024: report

    Listen to this article

    Estimated 4 minutes

    The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results.

    Alberta’s rate cap is deepening financial losses in the province’s auto insurance market, industry experts say, as a new report found auto insurers lost more than $1.2 billion in 2024.

    The latest annual report from Alberta’s superintendent of insurance, released last month, cited the Calgary hailstorm and the Jasper wildfire as major factors driving the loss.

    As a result, the Insurance Bureau of Canada (IBC), the national industry association, said insurers had to pay out 18 per cent more in claims than drivers paid in premiums. About 35 auto insurers in Alberta suffered a financial loss that year.

    “The superintendent expects this pressure on Alberta’s automobile insurance profitability and stability to continue through 2025,” the annual report says.

    Aaron Sutherland, IBC’s vice-president of Pacific and Western regions, said provincially regulated rate caps and high legal costs are factors that make it difficult for insurance companies to operate in the province.

    “We’ve seen multiple insurance companies forced to leave Alberta. That means less competition, less choice, and the insurers that remain here are restricting the sale of coverage,” Sutherland said.

    “It’s not improving affordability. In fact, it’s doing the opposite and it’s making auto insurance much more difficult to secure at a time when it’s needed the most.”

    The provincial government introduced the “good driver rate cap” in 2024, limiting the amount insurance premiums can go up in a given year.

    The cap was initially set around 3.7 per cent, then increased to 7.5 per cent in 2025.

    The annual report forecasts escalating claims costs will continue to exceed that cap due to inflation, growing severity of bodily injury claims, vehicle theft rates and weather-related losses.

    A portrait of a smiling man wearing a dusty pink button down dress shirt and grey blazer.
    Aaron Sutherland, the Insurance Burean of Canada’s vice-president for the Pacific and western regions, said insurance claim costs are rising and companies can’t raise premiums enough to keep up. (Insurance Bureau of Canada)

    “[The rate cap] pales in comparison to the growth and cost pressures underneath coverage —  legal costs, the cost of theft, the cost of natural disasters like hail events, those are going up well in excess of that,” he said.

    “With the cost of delivering coverage growing far faster than the price you’re able to charge, that simply isn’t sustainable.”

    Those observations ring true for Heather Mack, manager of education and engagement with the Alberta Automobile Insurance Rate Board, which sets auto insurance rates in the province.

    She said the biggest cost driver in auto insurance in Alberta is third-party liability or bodily injury — when the driver who isn’t at fault sues the other to compensate for things like medical costs and property damages.

    “We’ve seen a huge spike in the size of these awards — and it’s not money that’s definitely going to medical and rehab. [They are] significant legal awards and it’s driving up the cost of insurance for everyone,” Mack said.

    In a statement to CBC News, the Ministry of Treasury Board and Finance listed inflation, legal fees, more vehicle thefts, weather-related losses and tariffs as factors putting pressure on Alberta’s auto insurance market.

    Its list excluded the rate cap.

    New insurance model planned

    The Alberta government plans to implement the Care-First insurance model in 2027, which would settle the majority of injury claims without going to court.

    The system would resemble the publicly delivered “no-fault” systems in Manitoba, Saskatchewan and British Columbia, but it would be delivered by private insurers.

    The government’s announcement has been met with mixed messages. Some critics have said dangerous drivers would face less accountability and leave few options for drivers who have been injured in collisions.

    But Mack said, if done right, the new system would prioritize recovering people faster, “without lengthy delays and lawsuits being required,” while stabilizing the cost of auto insurance for all drivers.

    “That’s going to take a bit of a culture change, especially on the industry side,” she said, adding that the current system takes more of an adversarial approach.

    Continue Reading

  • Banks balk as Trump pushes for 1-year, 10% cap on credit card interest rates

    Banks balk as Trump pushes for 1-year, 10% cap on credit card interest rates

    NEW YORK (AP) — Reviving a campaign pledge, President Donald Trump wants a one-year, 10% cap on credit card interest rates, a move that could save Americans tens of billions of dollars but drew immediate opposition from an industry that has been in his corner.

    READ MORE: The economy is giving mixed signals. Here’s what experts say they mean

    Trump was not clear in his social media post Friday night whether a cap might take effect through executive action or legislation, though one Republican senator said he had spoken with the president and would work on a bill with his “full support.” Trump said he hoped it would be in place Jan. 20, one year after he took office.

    Strong opposition is certain from Wall Street in addition to the credit card companies, which donated heavily to his 2024 campaign and have supported Trump’s second-term agenda. Banks are making the argument that such a plan would most hurt poor people, at a time of economic concern, by curtailing or eliminating credit lines, driving them to high-cost alternatives like payday loans or pawnshops.

    “We will no longer let the American Public be ripped off by Credit Card Companies that are charging Interest Rates of 20 to 30%,” Trump wrote on his Truth Social platform.

    Researchers who studied Trump’s campaign pledge after it was first announced found that Americans would save roughly $100 billion in interest a year if credit card rates were capped at 10%. The same researchers found that while the credit card industry would take a major hit, it would still be profitable, although credit card rewards and other perks might be scaled back.

    About 195 million people in the United States had credit cards in 2024 and were assessed $160 billion in interest charges, the Consumer Financial Protection Bureau says. Americans are now carrying more credit card debt than ever, to the tune of about $1.23 trillion, according to figures from the New York Federal Reserve for the third quarter last year.

    Further, Americans are paying, on average, between 19.65% and 21.5% in interest on credit cards according to the Federal Reserve and other industry tracking sources. That has come down in the past year as the central bank lowered benchmark rates, but is near the highs since federal regulators started tracking credit card rates in the mid-1990s. That’s significantly higher than a decade ago, when the average credit card interest rate was roughly 12%.

    WATCH: Rising prices push many Americans further into credit card debt

    The Republican administration has proved particularly friendly until now to the credit card industry.

    Capital One got little resistance from the White House when it finalized its purchase and merger with Discover Financial in early 2025, a deal that created the nation’s largest credit card company. The Consumer Financial Protection Bureau, which is largely tasked with going after credit card companies for alleged wrongdoing, has been largely nonfunctional since Trump took office.

    In a joint statement, the banking industry was opposed to Trump’s proposal.

    “If enacted, this cap would only drive consumers toward less regulated, more costly alternatives,” the American Bankers Association and allied groups said.

    Bank lobbyists have long argued that lowering interest rates on their credit card products would require the banks to lend less to high-risk borrowers. When Congress enacted a cap on the fee that stores pay large banks when customers use a debit card, banks responded by removing all rewards and perks from those cards. Debit card rewards only recently have trickled back into consumers’ hands. For example, United Airlines now has a debit card that gives miles with purchases.

    The U.S. already places interest rate caps on some financial products and for some demographics. The Military Lending Act makes it illegal to charge active-duty service members more than 36% for any financial product. The national regulator for credit unions has capped interest rates on credit union credit cards at 18%.

    Credit card companies earn three streams of revenue from their products: fees charged to merchants, fees charged to customers and the interest charged on balances. The argument from some researchers and left-leaning policymakers is that the banks earn enough revenue from merchants to keep them profitable if interest rates were capped.

    “A 10% credit card interest cap would save Americans $100 billion a year without causing massive account closures, as banks claim. That’s because the few large banks that dominate the credit card market are making absolutely massive profits on customers at all income levels,” said Brian Shearer, director of competition and regulatory policy at the Vanderbilt Policy Accelerator, who wrote the research on the industry’s impact of Trump’s proposal last year.

    There are some historic examples that interest rate caps do cut off the less creditworthy to financial products because banks are not able to price risk correctly. Arkansas has a strictly enforced interest rate cap of 17% and evidence points to the poor and less creditworthy being cut out of consumer credit markets in the state. Shearer’s research showed that an interest rate cap of 10% would likely result in banks lending less to those with credit scores below 600.

    The White House did not respond to questions about how the president seeks to cap the rate or whether he has spoken with credit card companies about the idea.

    Sen. Roger Marshall, R-Kan., who said he talked with Trump on Friday night, said the effort is meant to “lower costs for American families and to reign in greedy credit card companies who have been ripping off hardworking Americans for too long.”

    Legislation in both the House and the Senate would do what Trump is seeking.

    Sens. Bernie Sanders, I-Vt., and Josh Hawley, R-Mo., released a plan in February that would immediately cap interest rates at 10% for five years, hoping to use Trump’s campaign promise to build momentum for their measure.

    Hours before Trump’s post, Sanders said that the president, rather than working to cap interest rates, had taken steps to deregulate big banks that allowed them to charge much higher credit card fees.

    Reps. Alexandria Ocasio-Cortez, D-N.Y., and Anna Paulina Luna, R-Fla., have proposed similar legislation. Ocasio-Cortez is a frequent political target of Trump, while Luna is a close ally of the president.

    Seung Min Kim reported from West Palm Beach, Fla.

    A free press is a cornerstone of a healthy democracy.

    Support trusted journalism and civil dialogue.


    Continue Reading

  • Military Access, Mobility & Safety Improvement Project Week of Jan. 11, 2026 — Colorado Department of Transportation

    Military Access, Mobility & Safety Improvement Project Week of Jan. 11, 2026 — Colorado Department of Transportation

    Colorado Springs — There will be various north- and southbound South Academy Boulevard lane closures on Monday, Jan. 12 through Friday, Jan. 16, 7 a.m. to 4:30 p.m. between Venetucci Boulevard and Milton Proby Parkway to allow crews to install signage and perform remaining roadway, traffic signal and lighting work. Two lanes of traffic will be maintained in both directions. Drivers should obey posted speed limits, maintain safe following distances and stay alert for crews and equipment in the work zone.

    Traffic Impacts

    South Academy Boulevard Widening Project

    • Various lane closures of north- and southbound South Academy Boulevard between Venetucci Boulevard and Milton Proby Parkway
      • Monday, Jan. 12 through Friday, Jan. 16, 7 a.m. to 4:30 p.m.
      • Two lanes of traffic will be maintained
    • Pay attention to signage

    Project Overview

    South Academy Boulevard Widening Project
    The improvements to South Academy Boulevard in this project are located on South Academy Boulevard at the southern mile and a half of this arterial road from the I-25 interchange, crossing US 85/87, and continuing to the road’s approach to Milton E. Proby Parkway (which connects to Powers Boulevard/CO 21). Construction focuses on widening an approximately 1.5-mile section of South Academy Boulevard from two lanes to three in each direction to alleviate recurring congestion. The project includes improved drainage facilities, lighting, striping, and expanded shoulders, modified merge lanes, sound walls and bridgework. The project is expected to be complete by early 2026. This project is managed by El Paso County.

    Safety Benefits

    CDOT conducted a safety assessment for the corridor to evaluate the magnitude and nature of safety problems and analyze the causes of crashes. These transportation improvements are mitigation measures to reduce crashes, improve infrastructure, and address physical deficiencies that contribute to crashes in the corridor. Over the next 20 years, the project is estimated to result in fewer deaths, injuries and crashes on the four MAMSIP corridors.

    Project Information

    For additional information about this project:

    About the Military Access, Mobility & Safety Improvement Program Build Grant

    Colorado Department of Transportation (CDOT) has initiated a program to deliver more efficient and safer mobility along I-25, Colorado Highway 94, South Academy Boulevard, and Charter Oak Ranch Road, enabling economic stability and development. The Military Access, Mobility & Safety Improvement Program is partially funded through an $18 million BUILD grant award from the US Department of Transportation. The delivery of these improvements will strengthen and enhance the redundancy of strategic movement between the nationally significant El Paso County military installations of Fort Carson, Peterson Space Force Base, Cheyenne Mountain Space Force Station, and Schriever Space Force Base.

    Know Before You Go

    Travelers are urged to “know before you go.” Gather information about weather forecasts and anticipated travel impacts and current road conditions prior to hitting the road. CDOT resources include:

    Remember: Slow For The Cone Zone

    The following tips are to help you stay safe while traveling through maintenance and construction work zones.

    • Do not speed in work zones. Obey the posted speed limits.
    • Stay Alert! Expect the unexpected.
    • Watch for workers. Drive with caution.
    • Don’t change lanes unnecessarily.
    • Avoid using mobile devices such as phones while driving in work zones.
    • Turn on headlights so that workers and other drivers can see you.
    • Be especially alert at night while driving in work zones.
    • Expect delays, especially during peak travel times.
    • Allow ample space between you and the car in front of you.
    • Anticipate lane shifts and merge when directed to do so.
    • Be patient!

    Download the COtrip App!

    The new free COtrip Planner mobile app was designed to meet the growing trend of information on mobile and tablet devices for the traveling public. The COtrip Planner app provides statewide, real-time traffic information, and works on mobile devices that operate on the iOS and Android platforms. Visit the Google Play Store (Android devices) or the Apple Store (iOS devices) to download!


    Continue Reading

  • Trump 2.0 tariff tracker – Trade Compliance Resource Hub

    1. Trump 2.0 tariff tracker  Trade Compliance Resource Hub
    2. About Those Trump Tariffs….  Drezner’s World
    3. What Can History Tell Us About Tariff Shocks?  Federal Reserve Bank of San Francisco
    4. Simple, informative charts break down the effect of Trump’s erratic tariff rollout  ap.org
    5. Tariffs Not Responsible for Inflation, Studies Say  AdvancedManufacturing.org

    Continue Reading

  • Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

    • Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without bevacizumab
    • The BREAKWATER study demonstrates clinically meaningful and statistically significant results, which show potential flexibility in chemotherapy backbone for patients with BRAF V600E-mutant metastatic colorectal cancer

    NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) assessed by blinded independent central review (BICR) compared to patients receiving standard-of-care treatment FOLFIRI with or without bevacizumab (64.4% vs 39.2%, odds ratio =2.76, p=0.001). These data will be presented today in an oral presentation (Abstract 13) at the 2026 American Society of Clinical Oncology Gastrointestinal (ASCO GI®) Cancers Symposium and highlighted in the ASCO GI official press program.

    “These results represent a great advance for patients with BRAF V600E-mutant metastatic colorectal cancer. We’ve seen this approach significantly increase the response compared to FOLFIRI with or without bevacizumab, and these responses were rapid and durable,” said Scott Kopetz, M.D., Ph.D., FACP, Professor and Deputy Chair of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center and co-principal investigator of the BREAKWATER trial. “The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population.”

    The estimated median duration of response as assessed by BICR was not estimable with BRAFTOVI plus cetuximab and FOLFIRI (95% Confidence Interval [CI]: not estimable [NE]-NE) or with FOLFIRI with or without bevacizumab (95% CI: 7.0 months-NE). Of patients on BRAFTOVI plus cetuximab and FOLFIRI, 57.4% had a response lasting 6 months or longer, compared to 34.5% with FOLFIRI with or without bevacizumab.

    Overall survival (OS) data were analyzed descriptively (Hazard Ratio [HR]: 0.49, 95% CI: 0.24-1.03; median follow-up of approximately 10 months for both arms). The BREAKWATER trial is ongoing with an estimated completion in 2027.

    “These data further strengthen the potential utility of BRAFOTVI for patients with BRAF V600E-mutant metastatic colorectal cancer. The significant improvement in response rates reflects the meaningful clinical benefit of this targeted combination therapy regimen for patients,” said Jeff Legos, Chief Oncology Officer, Pfizer. “These results underscore the potential of BRAFTOVI as a standard of care for patients with this aggressive cancer and reflect our commitment to advancing precision medicine options that help tailor treatment based on patients’ needs.”

    The safety profile of BRAFTOVI in combination with cetuximab and FOLFIRI was consistent with the known safety profile of each respective agent. No new safety signals were identified. The most common side effects (≥15%) were nausea, diarrhea, vomiting, alopecia, anemia, neutrophil count decreased, decreased appetite, fatigue, neutropenia, skin hyperpigmentation, dry skin, asthenia, weight decreased, arthralgia, palmar-plantar erythrodysaesthesia syndrome, rash, white blood cell count decreased, and constipation. Among patients receiving BRAFTOVI in combination with cetuximab and FOLFIRI, 8.5% experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI.

    BRAFTOVI in combination with cetuximab and FOLFIRI is an investigational regimen and is not currently approved for use. BRAFTOVI in combination with cetuximab and mFOLFOX6 received accelerated approval by the U.S. Food and Drug Administration (FDA) in December 2024 for patients with BRAF V600E -mutant mCRC based on a clinically meaningful and statistically significant improvement in confirmed ORR in treatment-naïve patients, one of the study’s primary endpoints. Continued approval for this indication is contingent upon verification of clinical benefit.

    Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (APLS) for company-sponsored research being presented, which are written in non-technical language. Those interested in learning more can visit www.Pfizer.com/apls to access the summaries.

    About BREAKWATER 
    BREAKWATER is a Phase 3, randomized, active-controlled, open-label, multicenter trial of BRAFTOVI with cetuximab, alone or in combination with chemotherapy (mFOLFOX6 or FOLFIRI) in participants with previously untreated BRAF V600E-mutant mCRC. Patients were randomized to receive BRAFTOVI 300 mg orally once daily in combination with cetuximab (discontinued after randomization of 158 patients), BRAFTOVI 300 mg orally once daily in combination with cetuximab and mFOLFOX6 (n=236) or mFOLFOX6, FOLFOXIRI, or CAPOX, with or without bevacizumab (control arm) (n=243). The dual primary endpoints for these study groups are ORR and PFS as assessed by BICR. OS is a key secondary endpoint. In Cohort 3, patients were randomized to receive BRAFTOVI 300 mg orally once daily in combination with cetuximab and FOLFIRI (n=73) or FOLFIRI, with or without bevacizumab (control-arm) (n=74). The primary endpoint of Cohort 3 is ORR as assessed by BICR. PFS is a key secondary endpoint; OS is a secondary endpoint.

    About Colorectal Cancer (CRC) 
    CRC is the third most common type of cancer in the world, with approximately 1.8 million new diagnoses in 2022.1 It is the second leading cause of cancer-related deaths.2 Overall, the lifetime risk of developing CRC is about 1 in 24 for men and 1 in 26 for women.2 In the U.S. alone, an estimated 154,270 people will be diagnosed with cancer of the colon or rectum in 2025, and approximately 53,000 are estimated to die from the disease each year.3 For 20% of those diagnosed with CRC, the disease has metastasized, or spread, making it harder to treat, and up to 50% of patients with localized disease eventually develop metastases.4

    BRAF mutations are estimated to occur in 8-12% of people with mCRC and are associated with a poor prognosis for these patients.5 The BRAF V600E mutation is the most common BRAF mutation and the risk of mortality in CRC patients with the BRAF V600E mutation is more than double that of patients with no known mutation present.5-7 Despite the high unmet need in BRAF V600E-mutant mCRC, prior to December 20, 2024, there were no approved biomarker-driven therapies specifically indicated for people with previously untreated BRAF V600E-mutant mCRC.8,9

    About BRAFTOVI® (encorafenib) 
    BRAFTOVI is an oral small molecule kinase inhibitor that targets BRAF V600E. Inappropriate activation of proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK) has been shown to occur in certain cancers, including CRC.

    Pfizer has exclusive rights to BRAFTOVI in the U.S., Canada, Latin America, Middle East, and Africa. Ono Pharmaceutical Co., Ltd. has exclusive rights to commercialize the product in Japan and South Korea, Medison has exclusive rights to commercialize the product in Israel and Pierre Fabre Laboratories has exclusive rights to commercialize the product in all other countries, including Europe and Asia (excluding Japan and South Korea).

    INDICATION AND USAGE 
    BRAFTOVI® (encorafenib) is indicated, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

    BRAFTOVI is also indicated, in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

    Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF CRC.

    IMPORTANT SAFETY INFORMATION

    Refer to the prescribing information for cetuximab and individual product components of mFOLFOX6 for recommended dosing and additional safety information.

    WARNINGS AND PRECAUTIONS

    New Primary Malignancies: New primary malignancies, cutaneous and non-cutaneous, can occur. In BEACON CRC (previously treated BRAF V600E mutation-positive mCRC), cutaneous squamous cell carcinoma (cuSCC), including keratoacanthoma (KA), occurred in 1.4% of patients with CRC, and a new primary melanoma occurred in 1.4% of patients who received BRAFTOVI in combination with cetuximab. In BREAKWATER (previously untreated BRAF V600E mutation-positive mCRC) skin papilloma was reported in 2.6%, basal cell carcinoma in 1.3%, squamous cell carcinoma of skin in 0.9%, keratoacanthoma in 0.4% and malignant melanoma in situ in 0.4% of patients who received BRAFTOVI in combination with cetuximab and mFOLFOX6. Perform dermatologic evaluations prior to initiating treatment, every 2 months during treatment, and for up to 6 months following discontinuation of treatment. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Dose modification is not recommended for new primary cutaneous malignancies. Based on its mechanism of action, BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms. Monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies. Discontinue BRAFTOVI for RAS mutation-positive non-cutaneous malignancies. Monitor patients for new malignancies prior to initiation of treatment, while on treatment, and after discontinuation of treatment.

    Tumor Promotion in BRAF Wild-Type Tumors: In vitro experiments have demonstrated paradoxical activation of MAP-kinase signaling and increased cell proliferation in BRAF wild-type cells exposed to BRAF inhibitors. Confirm evidence of BRAF V600E or V600K mutation using an FDA-approved test prior to initiating BRAFTOVI.

    Cardiomyopathy: Cardiomyopathy manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients. Assess left ventricular ejection fraction (LVEF) by echocardiogram or multi-gated acquisition (MUGA) scan prior to initiating treatment, 1 month after initiating treatment, and then every 2 to 3 months during treatment. Safety has not been established in patients with a baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN). Patients with cardiovascular risk factors should be monitored closely. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.

    Hepatotoxicity: Hepatotoxicity can occur. In BREAKWATER (previously untreated BRAF V600E mutation-positive mCRC), the incidence of Grade 3 or 4 increases in liver function laboratory tests in patients receiving BRAFTOVI in combination with cetuximab and mFOLFOX6 was 2.2% for alkaline phosphatase, 1.3% for ALT, and 0.9% for AST. Monitor liver laboratory tests before initiation of BRAFTOVI, monthly during treatment, and as clinically indicated. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.

    Hemorrhage: In BEACON CRC (previously treated BRAF V600E mutation-positive mCRC), hemorrhage occurred in 19% of patients receiving BRAFTOVI in combination with cetuximab; Grade 3 or higher hemorrhage occurred in 1.9% of patients, including fatal gastrointestinal hemorrhage in 0.5% of patients. The most frequent hemorrhagic events were epistaxis (6.9%), hematochezia (2.3%), and rectal hemorrhage (2.3%). In BREAKWATER (previously untreated BRAF V600E mutation-positive mCRC), hemorrhage occurred in 30% of patients receiving BRAFTOVI in combination with cetuximab and mFOLFOX6; Grade 3 or 4 hemorrhage occurred in 3% of patients. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.

    Uveitis: Uveitis, including iritis and iridocyclitis, has been reported in patients treated with BRAFTOVI. Assess for visual symptoms at each visit. Perform an ophthalmological evaluation at regular intervals and for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.

    QT Prolongation: BRAFTOVI is associated with dose-dependent QTc interval prolongation in some patients. In BREAKWATER (previously untreated BRAF V600E mutation-positive mCRC), an increase of QTcF >500 ms was measured in 3.6% (8/222) of patients receiving BRAFTOVI in combination with cetuximab and mFOLFOX6. Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during BRAFTOVI administration. Withhold, reduce dose, or permanently discontinue for QTc >500 ms.

    Embryo-Fetal Toxicity: BRAFTOVI can cause fetal harm when administered to pregnant women. BRAFTOVI can render hormonal contraceptives ineffective. Advise females of reproductive potential to use effective nonhormonal contraception during treatment with BRAFTOVI and for 2 weeks after the final dose.

    Risks Associated with Combination Treatment: BRAFTOVI is indicated for use as part of a regimen in combination with cetuximab, or in combination with cetuximab and mFOLFOX6. Refer to the prescribing information for cetuximab and individual product components of mFOLFOX6 for additional risk information.

    Lactation: Advise women not to breastfeed during treatment with BRAFTOVI and for 2 weeks after the final dose.

    Infertility: Advise males of reproductive potential that BRAFTOVI may impair fertility.

    ADVERSE REACTIONS

    BREAKWATER Trial (previously untreated BRAF V600E mutation-positive mCRC)

    • Serious adverse reactions occurred in 38% of patients who received BRAFTOVI in combination with cetuximab and mFOLFOX6. Serious adverse reactions in >3% of patients included intestinal obstruction (3.5%) and pyrexia (3.5%).
    • Fatal gastrointestinal perforation occurred in 0.9% of patients who received BRAFTOVI in combination with cetuximab and mFOLFOX6.
    • Most common adverse reactions(≥25%, all grades) in the BRAFTOVI with cetuximab and mFOLFOX6 arm compared to the control arm (mFOLFOX6 ± bevacizumab or FOLFOXIRI ± bevacizumab or CAPOX ± bevacizumab) were peripheral neuropathy (62% vs 53%), nausea (51% vs 48%), fatigue (49% vs 38%), rash (31% vs 4%), diarrhea (34% vs 47%), decreased appetite (33% vs 25%), vomiting (33% vs 21%), hemorrhage (30% vs 18%), abdominal pain (26% vs 27%), and pyrexia (26% vs 14%).
    • Most common laboratory abnormalities(≥10%, grade 3 or 4) in the BRAFTOVI with cetuximab and mFOLFOX6 arm compared to the control arm (mFOLFOX6 ± bevacizumab or FOLFOXIRI ± bevacizumab or CAPOX ± bevacizumab) were: increased lipase (51% vs 25%), decreased neutrophil count (36% vs 34%), decreased hemoglobin (13% vs 5%), decreased white blood cell count (12% vs 7%), and increased glucose (11% vs 2%).

    BEACON CRC Trial (previously treated BRAF V600E mutation-positive mCRC)

    • Most common adverse reactions(≥25%, all grades) in the BRAFTOVI with cetuximab arm compared to irinotecan with cetuximab or FOLFIRI with cetuximab (control) were: fatigue (51% vs 50%), nausea (34% vs 41%), diarrhea (33% vs 48%), dermatitis acneiform (32% vs 43%), abdominal pain (30% vs 32%), decreased appetite (27% vs 27%), arthralgia (27% vs 3%), and rash (26% vs 26%).
    • Other clinically important adverse reactions occurring in <10% of patients who received BRAFTOVI in combination with cetuximab was pancreatitis.
    • Most common laboratory abnormalities(all grades) (≥20%) in the BRAFTOVI with cetuximab arm compared to irinotecan with cetuximab or FOLFIRI with cetuximab (control) were: anemia (34% vs 48%) and lymphopenia (24% vs 35%).

    DRUG INTERACTIONS

    Strong or moderate CYP3A4 inhibitors: Avoid coadministration of BRAFTOVI with strong or moderate CYP3A4 inhibitors, including grapefruit juice. If coadministration is unavoidable, reduce the BRAFTOVI dose.

    Strong CYP3A4 inducers: Avoid coadministration of BRAFTOVI with strong CYP3A4 inducers.

    Sensitive CYP3A4 substrates: Avoid the coadministration of BRAFTOVI with CYP3A4 substrates (including hormonal contraceptives) for which a decrease in plasma concentration may lead to reduced efficacy of the substrate. If the coadministration cannot be avoided, see the CYP3A4 substrate product labeling for recommendations.

    Dose reductions of drugs that are substrates of OATP1B1, OATP1B3, or BCRP may be required when used concomitantly with BRAFTOVI.

    Avoid coadministration of BRAFTOVI with drugs known to prolong QT/QTc interval.

    View the full Prescribing Information.

    About Pfizer Oncology 
    At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

    About Pfizer: Breakthroughs That Change Patients’ Lives 
    At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

    Disclosure Notice 
    The information contained in this release is as of January 10, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

    This release contains forward-looking information about the BRAFTOVI® (encorafenib) plus cetuximab and FOLFIRI combination for the potential treatment of metastatic colorectal cancer (CRC) with a BRAF V600E mutation, including their potential benefits and ongoing clinical development program, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of BRAFTOVI; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether the BREAKWATER trial will meet the secondary endpoints of PFS and OS for Cohort 3; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications may be filed in any jurisdictions for BRAFTOVI plus cetuximab and FOLFIRI for the treatment of patients with metastatic CRC with a BRAF V600E mutation or for any other potential indications for BRAFTOVI; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether BRAFTOVI plus cetuximab and FOLFIRI will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of BRAFTOVI or BRAFTOVI plus cetuximab and FOLFIRI; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

    A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

    ERBITUX® is a registered trademark of Eli Lilly and Company its subsidiaries, or affiliates.

    References

    1. American Cancer Society. Global Cancer Facts & Figures 5th Edition. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf. Last accessed: November 2025.
    2. American Cancer Society. Key Statistics for Colorectal Cancer. Available at: https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html. Last accessed: November 2025.
    3. American Cancer Society. Cancer Facts & Figures 2025. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf. Last accessed: November 2025.
    4. Ciardiello F, Ciardiello D, Martini G, et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72:372–40.
    5. Josep Tabernero et al. The Evolving Treatment Landscape in BRAF-V600E–Mutated Metastatic Colorectal Cancer. Am Soc Clin Oncol Educ Book. 2022;42:254-263. doi:10.1200/EDBK_349561
    6. Safaee Ardekani G, Jafarnejad SM, Tan L, et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PloS ONE. 2012;7(10):e47054.
    7. Schirripa M, Biason P, Lonardi S, et al. Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clin Cancer Res. 2019;25(13):3954-3961. doi:10.1158/1078-0432.CCR-19-0311
    8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Colon Cancer. V.5.2025 © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.
    9. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32.

     

    Source: Pfizer Inc.

    Continue Reading

  • 4Q 2025 Earnings Call :: Exxon Mobil Corporation (XOM)

    4Q 2025 Earnings Call :: Exxon Mobil Corporation (XOM)

    4Q 2025 Earnings Call


    ExxonMobil is hosting its fourth-quarter 2025 earnings call from 8:30 a.m. to approximately 9:30 a.m. central time on Friday, January 30th. Presenters include Darren Woods, Chairman and Chief Executive Officer; Kathy Mikells, Senior Vice President and Chief Financial Officer; Neil Hansen, incoming Senior Vice President and Chief Financial Officer (effective February 1, 2026); and Jim Chapman, Vice President, Treasurer and Investor Relations. The presentation and formal remarks will be available on the Investor section of our website beginning on Friday, January 30th, at approximately 5:30 a.m. CT. Additional comments and Q&A will be shared via webcast starting at 8:30 a.m. CT.

    Listen only telephone dial-in:
    Start date/time: January 30, 2026, at 8:30 a.m. CT
    Call-in passcode: 8057011
    Local: +1 (720)-543-0311
    Toll-free: +1 (888)-572-7032

    Continue Reading